Document resource
Introduction Belantamab-mafodotin (Belamaf, GSK) is a 2nd line biologic for multiple myeloma which has been recently approved by NICE in the UK and FDA in the USA. In Moorfields we have been seeing myeloma patients for some years who are in belantamab-mafodotin clinical trials at UCL Hospital. Infusions are given 4-6 weekly. All or nearly all patients get a bilateral microcystic epithelial keratopathy which can significantly interfere with BSCVA and refraction; onset ~2-3 weeks post-infusion and it tends to clear without intervention after a few weeks. As ophthalmologists we recommend that scheduled infusions be paused in some patients to allow visual recovery (i.e. the haematologists need us to monitor). With regulatory approval there will be a nationwide uptake of this agent and corneal specialists need to get involved or delegate the monitoring. Implications and recommendations for care will be discussed.